drugset
drugset / Trial / NCT06477835

A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis

NCT06477835 ↗

Phase 3 Completed 259 enrolled Simcere Pharmaceutical Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the efficacy and safety of SIM0718 in adolescents (12- \< 18 years) and adults (18-75 years) with moderate to severe AD.

Timeline

Start
2024-07-04
Primary completion
2025-11-04
Completion
2025-12-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator SIM0718 Unknown 300 mg Subcutaneous

Indications

atopic eczema